<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>pharmaceuticals on FinanClub</title>
    <link>https://finan.club/tags/pharmaceuticals/</link>
    <description>Recent content in pharmaceuticals on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Mon, 22 Jan 2024 09:06:36 +0000</lastBuildDate><atom:link href="https://finan.club/tags/pharmaceuticals/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>JNJ</title>
      <link>https://finan.club/us/jnj/</link>
      <pubDate>Mon, 22 Jan 2024 09:06:36 +0000</pubDate>
      
      <guid>https://finan.club/us/jnj/</guid>
      <description>score:18
Chances: This company is currently firing on all cylinders. Most readers would already know that Johnson &amp;amp; Johnson&amp;rsquo;s (NYSE:JNJ) stock increased by 6.8% over the past three months. These stocks may help you win in 2024 &amp;ndash; no matter what the market does.</description>
    </item>
    
    <item>
      <title>MRK</title>
      <link>https://finan.club/us/mrk/</link>
      <pubDate>Mon, 22 Jan 2024 09:05:50 +0000</pubDate>
      
      <guid>https://finan.club/us/mrk/</guid>
      <description>score:153
Chances: Merck &amp;amp; Co., Inc. has a strong portfolio of pharmaceutical, vaccine, and animal health products, positioning it well for future growth and profitability. The recent FDA approval for expanded use of Keytruda in combination with chemoradiotherapy for advanced cervical cancer is a significant positive development for the company.</description>
    </item>
    
    <item>
      <title>OGN</title>
      <link>https://finan.club/us/ogn/</link>
      <pubDate>Wed, 20 Dec 2023 09:03:44 +0000</pubDate>
      
      <guid>https://finan.club/us/ogn/</guid>
      <description>score:21
Chances: Organon&amp;rsquo;s partnership with Sempre Health to improve medication adherence shows a proactive approach to patient care and may lead to increased sales. The company&amp;rsquo;s exclusive distribution of Emgality and RAYVOW in Europe presents a significant opportunity for revenue growth in the region.</description>
    </item>
    
    <item>
      <title>AZN</title>
      <link>https://finan.club/us/azn/</link>
      <pubDate>Tue, 19 Dec 2023 09:06:54 +0000</pubDate>
      
      <guid>https://finan.club/us/azn/</guid>
      <description>score:-135
Chances: AstraZeneca (AZN) closed at $65.95, indicating a +1.77% shift from the previous trading day. AstraZeneca (AZN) announces that it is buying vaccine company, Icosavax. The additional supply of RSV shot for infants by AstraZeneca and Sanofi indicates a positive outlook for meeting winter demand.</description>
    </item>
    
  </channel>
</rss>
